{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T12:13:05Z","timestamp":1788178385217,"version":"build-2803163510"},"reference-count":51,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T00:00:00Z","timestamp":1710979200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Although checkpoint inhibitors (CPIs) have improved outcomes for patients with metastatic melanoma, those progressing on CPIs have limited therapeutic options. To address this unmet need and overcome CPI resistance mechanisms, novel immunotherapies, such as T-cell engaging agents, are being developed. The use of these agents has sometimes been limited by the immune response mounted against them in the form of anti-drug antibodies (ADAs), which is challenging to predict preclinically and can lead to neutralization of the drug and loss of efficacy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>TYRP1-TCB (RO7293583; RG6232) is a T-cell engaging bispecific (TCB) antibody that targets tyrosinase-related protein 1 (TYRP1), which is expressed in many melanomas, thereby directing T cells to kill TYRP1-expressing tumor cells. Preclinical studies show TYRP1-TCB to have potent anti-tumor activity. This first-in-human (FIH) phase 1 dose-escalation study characterized the safety, tolerability, maximum tolerated dose\/optimal biological dose, and pharmacokinetics (PK) of TYRP1-TCB in patients with metastatic melanoma (NCT04551352).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Twenty participants with cutaneous, uveal, or mucosal TYRP1-positive melanoma received TYRP1-TCB in escalating doses (0.045 to 0.4 mg). All participants experienced \u22651 treatment-related adverse event (TRAE); two participants experienced grade 3 TRAEs. The most common toxicities were grade 1\u20132 cytokine release syndrome (CRS) and rash. Fractionated dosing mitigated CRS and was associated with lower levels of interleukin-6 and tumor necrosis factor-alpha. Measurement of active drug (dual TYPR1- and CD3-binding) PK rapidly identified loss of active drug exposure in all participants treated with 0.4 mg in a flat dosing schedule for \u22653 cycles. Loss of exposure was associated with development of ADAs towards both the TYRP1 and CD3 domains. A total drug PK assay, measuring free and ADA-bound forms, demonstrated that TYRP1-TCB-ADA immune complexes were present in participant samples, but showed no drug activity <jats:italic>in vitro<\/jats:italic>.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>This study provides important insights into how the use of active drug PK assays, coupled with mechanistic follow-up, can inform and enable ongoing benefit\/risk assessment for individuals participating in FIH dose-escalation trials. Translational studies that lead to a better understanding of the underlying biology of cognate T- and B-cell interactions, ultimately resulting in ADA development to novel biotherapeutics, are needed.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2024.1346502","type":"journal-article","created":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T05:14:00Z","timestamp":1710998040000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":18,"title":["Phase 1, first-in-human study of TYRP1-TCB (RO7293583), a novel TYRP1-targeting CD3 T-cell engager, in metastatic melanoma: active drug monitoring to assess the impact of immune response on drug exposure"],"prefix":"10.3389","volume":"14","author":[{"given":"Anna","family":"Spreafico","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva Mu\u00f1oz","family":"Couselo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Irmisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana","family":"Bessa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Au-Yeung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Bechter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge Marie","family":"Svane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel F.","family":"Sanmamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Gambardella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meredith","family":"McKean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Callahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhard","family":"Dummer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Uma\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Justies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Heil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Fahrni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenia","family":"Opolka-Hoffmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inja","family":"Waldhauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conrad","family":"Bleul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland F.","family":"Staack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaios","family":"Karanikas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Fowler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,3,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02229","article-title":"Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma","volume":"40","author":"Wolchok","year":"2022","journal-title":"J Clin Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-2267","article-title":"Primary and acquired resistance to immune checkpoint inhibitors in metastatic melanoma","volume":"24","author":"Gide","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B6","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41577-019-0218-4","article-title":"Tumour-intrinsic resistance to immune checkpoint blockade","volume":"20","author":"Kalbasi","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1696","article-title":"A novel carcinoembryonic antigen T-cell bispecific antibody (CEA TCB) for the treatment of solid tumors","volume":"22","author":"Bacac","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-0612","article-title":"FDA approval: blinatumomab","volume":"21","author":"Przepiorka","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206913","article-title":"Glofitamab for relapsed or refractory diffuse large B-cell lymphoma","volume":"387","author":"Dickinson","year":"2022","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2103485","article-title":"Overall survival benefit with tebentafusp in metastatic uveal melanoma","volume":"385","author":"Nathan","year":"2021","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02823","article-title":"Tarlatamab, a first-in-class DLL3-targeted bispecific T-cell engager, in recurrent small-cell lung cancer: an open-label, phase I study","volume":"41","author":"Paz-Ares","year":"2023","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS8611","article-title":"Randomized phase 3 study of tarlatamab, a DLL3-targeting bispecific T-cell engager (BiTE), compared to standard of care in patients with relapsed small cell lung cancer (DeLLphi-304)","volume":"41","author":"Paz-Ares","year":"2023","journal-title":"J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.molonc.2011.01.006","article-title":"Tyrosinase related protein 1 (TYRP1\/gp75) in human cutaneous melanoma","volume":"5","author":"Ghanem","year":"2011","journal-title":"Mol Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-021-02597-7","article-title":"Association of TYRP1 with hypoxia and its correlation with patient outcome in uveal melanoma","volume":"23","author":"Jha","year":"2021","journal-title":"Clin Transl Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3233\/CBM-220093","article-title":"Expression and clinical significance of TYRP1, ABCB5, and MMP17 in sinonasal mucosal melanoma","volume":"35","author":"Tu","year":"2022","journal-title":"Cancer Biomark"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-1241","article-title":"An open-label, dose-escalation phase I study of anti-TYRP1 monoclonal antibody IMC-20D7S for patients with relapsed or refractory melanoma","volume":"22","author":"Khalil","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2021.1967714","article-title":"Ten years in the making: application of CrossMab technology for the development of therapeutic bispecific antibodies and antibody fusion proteins","volume":"13","author":"Surowka","year":"2021","journal-title":"mAbs"},{"key":"B18","doi-asserted-by":"publisher","first-page":"LB","DOI":"10.1158\/1538-7445.AM2020-LB-389","article-title":"Abstract LB-389: Combination of TYRP1-TCB, a novel T cell bispecific antibody for the treatment of melanoma, with immunomodulatory agents","volume":"80","author":"Nicolini","year":"2020","journal-title":"Cancer Res"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01951","article-title":"The molecular mechanisms that underlie the immune biology of anti-drug antibody formation following treatment with monoclonal antibodies","volume":"11","author":"Vaisman-Mentesh","year":"2020","journal-title":"Front Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12742","article-title":"From the bench to clinical practice: understanding the challenges and uncertainties in immunogenicity testing for biopharmaceuticals","volume":"184","author":"Gunn","year":"2016","journal-title":"Clin Exp Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2012.10.021","article-title":"Immunogenicity and autoimmunity during anti-TNF therapy","volume":"12","author":"Atzeni","year":"2013","journal-title":"Autoimmun Rev"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011931","article-title":"Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin","volume":"14","author":"Casadevall","year":"2002","journal-title":"N Engl J Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.742695","article-title":"Induction of tolerance to therapeutic proteins with antigen-processing independent T cell epitopes: controlling immune responses to biologics","volume":"12","author":"Schurgers","year":"2021","journal-title":"Front Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.885672","article-title":"Immunogenicity of monoclonal antibodies and the potential use of HLA haplotypes to predict vulnerable patients","volume":"13","author":"Mosch","year":"2022","journal-title":"Front Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2021.03.027","article-title":"Managing the impact of immunogenicity in an era of immunotherapy: from bench to bedside","volume":"110","author":"Bray-French","year":"2021","journal-title":"J Pharm Sci"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2017.09.001","article-title":"An FDA oncology analysis of CD3 bispecific constructs and first-in-human dose selection","volume":"90","author":"Saber","year":"2017","journal-title":"Regul Toxicol Pharmacol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"B28","unstructured":"Bioanalytical method validation - guidance for industry2018"},{"key":"B29","unstructured":"Guideline on bioanalytical method validation2011"},{"key":"B30","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1208\/s12248-011-9251-3","article-title":"Bioanalytical approaches to quantify \"total\" and \"free\" therapeutic antibodies and their targets: technical challenges and PK\/PD applications over the course of drug development","volume":"13","author":"Lee","year":"2011","journal-title":"AAPS J"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.4155\/bio.11.321","article-title":"Mathematical simulations for bioanalytical assay development: the (un-)necessity and (im-)possibility of free drug quantification","volume":"4","author":"Staack","year":"2012","journal-title":"Bioanalysis"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.4155\/bio.13.316","article-title":"Free analyte QC concept: a novel approach to prove correct quantification of free therapeutic protein drug\/biomarker concentrations","volume":"6","author":"Staack","year":"2014","journal-title":"Bioanalysis"},{"key":"B33","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.jpba.2015.05.029","article-title":"Epitope characterization of the ADA response directed against a targeted immunocytokine","volume":"114","author":"Stubenrauch","year":"2015","journal-title":"J Pharm Biomed Anal"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2021.1995929","article-title":"The impact of immunogenicity on therapeutic antibody pharmacokinetics: a preclinical evaluation of the effect of immune complex formation and antibody effector function on clearance","volume":"13","author":"Opolka-Hoffmann","year":"2021","journal-title":"mAbs"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-1247","article-title":"Tebentafusp, A TCR\/Anti-CD3 bispecific fusion protein targeting gp100, potently activated antitumor immune responses in patients with metastatic melanoma","volume":"26","author":"Middleton","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2307980","article-title":"Tarlatamab for patients with previously treated small-cell lung cancer","volume":"389","author":"Ahn","year":"2023","journal-title":"N Engl J Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-06-651380","article-title":"Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed\/refractory diffuse large B-cell lymphoma","volume":"127","author":"Viardot","year":"2016","journal-title":"Blood"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.7518","article-title":"Managing cytokine release syndrome (CRS) and neurotoxicity with step-fractionated dosing of mosunetuzumab in relapsed\/refractory (R\/R) B-cell non-Hodgkin lymphoma (NHL)","volume":"37","author":"Bartlett","year":"2019","journal-title":"J Clin Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00931","article-title":"Single-agent mosunetuzumab shows durable complete responses in patients with relapsed or refractory B-cell lymphomas: phase I dose-escalation study","volume":"40","author":"Budde","year":"2022","journal-title":"J Clin Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aax8861","article-title":"CD3 bispecific antibody-induced cytokine release is dispensable for cytotoxic T cell activity","volume":"11","author":"Li","year":"2019","journal-title":"Sci Transl Med"},{"key":"B41","first-page":"293","article-title":"The protein expression of TRP-1 and galectin-1 in cutaneous Malignant melanomas","volume":"5","author":"Bolander","year":"2008","journal-title":"Cancer Genom Proteom"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.4155\/bio-2021-0116","article-title":"A survey of pharmacokinetic bioanalytical methods in biosimilar biological license applications for the assessment of target and antidrug antibody effects","volume":"13","author":"Hackel","year":"2021","journal-title":"Bioanalysis"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213299","article-title":"Restricted immune activation and internalisation of anti-idiotype complexes between drug and antidrug antibodies","volume":"77","author":"van Schie","year":"2018","journal-title":"Ann Rheumatol Dis"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.4155\/bio.15.213","article-title":"Quantification of a bifunctional drug in the presence of an immune response: a ligand-binding assay specific for 'active' drug","volume":"7","author":"Staack","year":"2015","journal-title":"Bioanalysis"},{"key":"B45","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1111\/cei.12858","article-title":"Circulating T cells to infliximab are detectable mainly in treated patients developing anti-drug antibodies and hypersensitivity reactions","volume":"186","author":"Vultaggio","year":"2016","journal-title":"Clin Exp Immunol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20052036","article-title":"T-independent type II immune responses generate memory B cells","volume":"203","author":"Obukhanych","year":"2006","journal-title":"J Exp Med"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0802317","article-title":"T-independent antibody responses to T-dependent antigens: a novel follicular dendritic cell-dependent activity","volume":"182","author":"El Shikh","year":"2009","journal-title":"J Immunol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2016-0061","article-title":"Antidrug antibody formation in oncology: clinical relevance and challenges","volume":"21","author":"van Brummelen","year":"2016","journal-title":"Oncologist"},{"key":"B49","doi-asserted-by":"publisher","first-page":"37","DOI":"10.2147\/btt.s145941","article-title":"Correlation between HLA haplotypes and the development of antidrug antibodies in a cohort of patients with rheumatic diseases","volume":"12","author":"Benucci","year":"2018","journal-title":"Biologics"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0159328","article-title":"Use of in vitro assays to assess immunogenicity risk of antibody-based biotherapeutics","volume":"11","author":"Joubert","year":"2016","journal-title":"PloS One"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2022.2143009","article-title":"Enhanced immunogenic potential of cancer immunotherapy antibodies in human IgG1 transgenic mice","volume":"14","author":"Egli","year":"2022","journal-title":"mAbs"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1346502\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T05:14:05Z","timestamp":1710998045000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1346502\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,21]]},"references-count":51,"alternative-id":["10.3389\/fonc.2024.1346502"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2024.1346502","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,21]]},"article-number":"1346502"}}